x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology On The Go

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology

science medicine

All Episodes

13:27

S1 Ep156: Elevating the Quality of Cancer Care Via...

Oncology On The Go ·

2025/04/07

CancerNetwork® visited Sibley Memorial Hospital of Johns Hopkins Medicine to speak with a variety of experts about therapeutic advancements and ongoing research initiatives across several different cancer fields. As part of each discussion, clinicians highlighted how collaboration across different departments has positively impacted treatment planning, decision-making, and outcomes at their institution.These experts included the following: · Rachit Kumar, MD, an assistant professor of

en-us

11:10

S1 Ep155: Improving NSCLC Surgery Recovery After...

Oncology On The Go ·

2025/03/31

In a conversation with CancerNetwork®, Leticia Nogueira, PhD, MPH, highlighted the findings and implications of a study she published that evaluated how exposure to wildfires affected post-operative length of stay (LOS) among patients who were recovering from surgery for non–small cell lung cancer (NSCLC). Data from this study showed that patients who underwent curative-intent surgery at facilities exposed to a wildfire disaster experienced a longer LOS compared with similar patients who received

en-us

22:30

S1 Ep154: Considering Dosing and AE Management...

Oncology On The Go ·

2025/03/24

In the second edition of a special podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about the best practices for incorporating recently approved bispecific antibodies into cancer care. This discussion focused on clinical trial results, administration protocols, and adverse effect (AE) management strategies related to the use of tarlatamab-dlle (Imdelltra) for patients with small cell lung cancer (SCLC).Morgensztern is a

en-us

31:09

S1 Ep153: Redefining the Treatment Paradigm in Low...

Oncology On The Go ·

2025/03/17

Molecular differences in the profiles of low grade serous ovarian cancer (LGSOC) and high-grade SOC substantiate the need to find unique, differentiated treatment options for each epithelial ovarian cancer subtype, according to Kathleen N. Moore, MD, MS.CancerNetwork® spoke with Moore, Virginia Kerley Cade Endowed Chair of Cancer Development, associate director of Clinical Research at the Stephenson Cancer Center, director of the Oklahoma TSET Phase I Program and professor in the Section of

en-us

12:09

S1 Ep152: Oncologists Reflect on Pandemic's Lasting...

Oncology On The Go ·

2025/03/10

In a recent episode of Oncology on the Go, several oncologists discussed the impact of the COVID-19 pandemic on oncology care, 5 years later. Each doctor discussed a different aspect of multidisciplinary care, including medical oncology, radiation oncology, and epidemiology. CancerNetwork® spoke with leading clinicians including: · Aditya Bardia, MD, MPH, FSCO, professor in the Department of Medicine, Division of Hematology/Oncology, and director of Translational Research Integration at the

en-us

56:47

S1 Ep151: Key CAR T and Transplantation Presentations...

Oncology On The Go ·

2025/03/03

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center. The conversation took place during the 2025 Tandem Meeting and highlighted

en-us

10:21

S1 Ep150: Sotorasib Combo Approval May Address Novel...

Oncology On The Go ·

2025/02/24

In a conversation with CancerNetwork®, Marwan G. Fakih, MD, spoke about the FDA approval of sotorasib (Lumakras) plus panitumumab (Vectibix), and how it may affect the treatment paradigm for patients with KRAS G12C-mutant metastatic colorectal cancer (CRC).Fakih is a professor in the Department of Medical Oncology & Therapeutics Research, associate director for Clinical Sciences, medical director of the Briskin Center for Clinical Research, division chief of GI Medical Oncology, and

en-us

12:30

S1 Ep149: Highlighting Insights From the Marginal...

Oncology On The Go ·

2025/02/17

Following the 2024 Marginal Zone Lymphoma (MZL) Workshop, CancerNetwork® spoke with multiple attending clinicians about insights they shared regarding the disease state, covering the significance of the workshop and its contribution to advancing research in areas such as prognostic factors and managing adverse events (AEs) related to the disease. Thomas Habermann, MD, professor of Medicine at the Mayo Clinic in Rochester, Minnesota, member of the Lymphoma Research Foundation’s Scientific Advisory

en-us

26:34

S1 Ep148: Navigating Management and Dosing...

Oncology On The Go ·

2025/02/10

In the first edition of a special 3-part podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about best practices for implementing recently approved bispecific antibodies into cancer care. Their initial discussion focused on the clinical trial results, administration protocols, and toxicity management strategies related to the use of amivantamab-vmjw (Rybrevant) for patients with EGFR-mutated non–small cell lung cancer

en-us

18:04

S1 Ep147: Expanding and Advancing the Future of Renal...

Oncology On The Go ·

2025/02/03

In collaboration with KidneyCAN, CancerNetwork® spoke with Eric Jonasch, MD, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine, and the director of the von Hippel Lindau Center at the University of Texas MD Anderson Cancer Center in Houston, Texas, about the missions and goals of the Kidney Cancer Research Consortium.Jonasch is the principal investigator of an effort, supported by a Department of Defense (DoD)–funded grant, that aims to improve

en-us

11:05

S1 Ep146: Conducting Early Phase Trials of Promising...

Oncology On The Go ·

2025/01/27

In a conversation with CancerNetwork®, Shewetal Mehta, PhD, spoke about her research team’s focuses in moving novel brain cancer therapies down the pipeline as part of an early phase clinical trials program at the Ivy Brain Tumor Center.Mehta, the deputy director and pre-clinical core leader at the Ivy Brain Tumor Center of Barrow Neurological Institute in Phoenix, Arizona, underscored a scientifically rigorous, patient-driven philosophy that drives her team members to deliver timely answers to

en-us

16:29

S1 Ep145: Psilocybin May Help Address Cancer-Related...

Oncology On The Go ·

2025/01/20

CancerNetwork® spoke with Michael P. Bogenschutz, MD, director of the NYU Langone Center for Psychedelic Medicine and professor of Psychiatry at NYU Grossman School of Medicine, about psilocybin-assisted psychotherapy (PAP) in managing psychological challenges associated with serious cancer diagnoses following the publication of a pooled analysis of 2 phase 2 trials assessing the regimen in this patient population.In these trials, 87 patients were randomly assigned 1:1 to receive either psilocybin

en-us

41:02

S1 Ep144: SABCS 2024 Data Show ‘Great Steps Forward’...

Oncology On The Go ·

2025/01/13

Following the 2024 San Antonio Breast Cancer Symposium (SABCS), Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD, co-hosted a live X Space with CancerNetwork® and spoke about updated trial findings that may impact the breast cancer treatment paradigm.Tarantino is a clinical research fellow at Dana-Farber Cancer Institute and Harvard Medical School. Lambertini is an associate professor and consultant in medical oncology at the University of Genova – IRCCS Policlinico San Martino Hospital in

en-us

32:46

S1 Ep143: Using Multidisciplinary Lifestyle Medicine...

Oncology On The Go ·

2025/01/06

In a conversation with CancerNetwork®, Rachel A. Millstein, PhD, MHS; Loren Winters, NP; and Amy Comander, MD, discussed their article titled Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship, which was published in the November 2024 issue of ONCOLOGY®. The authors detailed the implementation of a novel oncology-based multidisciplinary lifestyle medicine clinic that may help enhance the quality of life (QOL) among survivors of cancer.Millstein is a psychologist in

en-us

18:46

S1 Ep142: Determining Suitable Radioligand Therapy...

Oncology On The Go ·

2024/12/30

CancerNetwork® spoke with Natasha Bahri, MD, MS, and Daneng Li, MD, about their Hot Topics article titled Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?, which was published in the November 2024 issue of ONCOLOGY®. Their article focused on findings related to the use of 177Lutetium-Dotatate (177Lu-dotatate; Lutathera) in patients with neuroendocrine tumors (NETs) and whether these data supported the use of the novel radioligand therapy for this population. Bahri is a

en-us

8:56

S1 Ep141: Reducing Post-Mastectomy Disparities in...

Oncology On The Go ·

2024/12/23

CancerNetwork® spoke with Rachel A. Greenup, MD, MPH, an associate professor of surgery (oncology), section chief of Breast Surgery, and co-director of the Center for Breast Cancer at the Yale School of Medicine, about the rationale behind conducting a study evaluating the lived experiences among women of color following breast cancer mastectomy, as well as data collection strategies employed during the study and key themes outlined in questionnaire responses. First, Greenup, senior author of the

en-us

12:09

S1 Ep140: Highlighting Advocacy Impacts on Funding...

Oncology On The Go ·

2024/12/16

CancerNetwork, in a partnership with KidneyCAN, spoke with 2 genitourinary oncologists, Elizabeth P. Henske, MD, and Jason Muhitch, PhD, about how advocacy and funding through interdisciplinary collaboration between patient advocates, researchers, and physicians have resulted in numerous clinical breakthroughs in kidney cancer. Henske is a professor of medicine at the Harvard Medical School, an associate member of the Broad Institute of MIT and Harvard, director of the Center for LAM Research and

en-us

16:34

S1 Ep139: Ensuring Holistic, Individualized...

Oncology On The Go ·

2024/12/09

In a conversation with CancerNetwork® at the 2024 Annual Oncology Clinical Practice and Research Summit, Andrew M. Evens, DO, MBA, MSc, spoke about a session he moderated at the meeting, in which he and other panelists highlighted ongoing efforts to improve the quality of care for cancer survivors at his institution. Evens is the deputy director for Clinical Services at Rutgers Cancer Institute and the system director of Medical Oncology and the oncology lead at RWJBarnabas Health Medical Group

en-us

25:03

S1 Ep138: Managing Risks, Planning Treatment, &...

Oncology On The Go ·

2024/12/02

During Pancreatic Cancer Awareness Month, CancerNetwork® spoke with Kelly A. Rone, DNP, RN, AGNP-c, about the current state of pancreatic cancer, emphasizing risk factors, diagnostic challenges, and treatment planning. Rone is an advanced practice nurse of gastrointestinal oncology at Mayo Clinic in Phoenix, Arizona.Rone initially discussed patient counseling for risk factors, making a distinction between modifiable risk factors—such as smoking, drinking, and obesity—and nonmodifiable risk

en-us

29:10

S1 Ep137: Advancing Research and Targeting Genomic...

Oncology On The Go ·

2024/11/25

In a conversation with CancerNetwork® during Pancreatic Cancer Awareness Month, Tanios S. Bekaii-Saab, MD, spoke about various developments in the pancreatic cancer treatment field. Throughout the discussion, Bekaii-Saab weighed the benefits of currently available chemotherapeutic regimens for patients with metastatic disease, discussed research on the potential for precision medicine in those with KRAS wildtype pancreatic ductal adenocarcinoma (PDAC), and detailed ongoing initiatives to improve

en-us

222 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter